In the GOYA-trial where CHOP + obinutuzumab was compared with R-CHOP for DLBCL patients >18 years, an estimated 3-year PFS of 67% was reported in the R-CHOP-arm23. Here, DDIT3 is linked to diffuse large B-cell lymphoma.